House Antidepressants Hearing To Include Six FDA Witnesses
This article was originally published in The Pink Sheet Daily
Executive Summary
House Energy & Commerce/Oversight Subcommittee hearing Sept. 23 will address FDA’s review of pediatric antidepressant data and is structured to pit the testimony of FDA Epidemiologist Andrew Mosholder against other agency officials.